In the present study, we evaluated the roles of type II and type III sodiumdependent Pi cotransporters in fibroblast growth factor 23 (FGF23) activity by administering a vector encoding FGF23 with the R179Q mutation (FGF23M) to wild-type (WT) mice, Npt2a knockout (KO) mice, Npt2c KO mice, and Npt2a Ϫ/Ϫ Npt2c Ϫ/Ϫ mice (DKO mice). In Npt2a KO mice, FGF23M induced severe hypophosphatemia and markedly decreased the levels of Npt2c, type III Na-dependent Pi transporter (PiT2) protein, and renal Na/Pi transport activity. In contrast, in Npt2c KO mice, FGF23M decreased plasma phosphate levels comparable to those in FGF23M-injected WT mice. In DKO mice with severe hypophosphatemia, FGF23M administration did not induce an additional increase in urinary phosphate excretion. FGF23 administration significantly decreased intestinal Npt2b protein levels in WT mice but had no effect in Npt2a, Npt2c, and DKO mice, despite marked suppression of plasma 1,25(OH)2D3 levels in all the mutant mice. The main findings were as follow: 1) FGF23-dependent phosphaturic activity in Npt2a KO mice is dependent on renal Npt2c and PiT-2 protein; 2) in DKO mice, renal Pi reabsorption is not further decreased by FGF23M, but renal vitamin D synthesis is suppressed; and 3) downregulation of intestinal Npt2b may be mediated by a factor(s) other than 1,25(OH) 2D3. These findings suggest that Npt2a, Npt2c, and PiT-2 are necessary for the phosphaturic activity of FGF23. Thus complementary regulation of Npt2 family proteins may be involved in systemic P i homeostasis.
INTESTINAL ABSORPTION AND renal excretion of P i are important for systemic P i homeostasis. The solute carriers of three distinct Na-dependent P i transporters [SLC34A1 (NaPi-IIa/ NPT2a), SLC34A2 (NaPi-IIb/NPT2b), and SLC34A3 (NaPiIIc/NPT2c)] are specifically expressed in the brush-border membrane (BBM) of intestinal and renal epithelial cells (4, 11, f23) . The type III Na-dependent P i transporter [SLC20A2 (PiT-2)] may be involved in intestinal and renal proximal tubular P i (re)absorption (26 -28) .
In the kidney, the NaPi-IIa transporter (Npt2a) has a major role in renal P i reabsorption, whereas NaPi-IIc (Npt2c) is important for P i reabsorption in weanling animals (4, 11, 23) but mediates only a very small percentage of P i reabsorption in adult animals (11, 23) . Recent findings indicate that a gene product of SLC20A2 (PiT-2) is also potentially involved in proximal tubular P i reabsorption as this protein is localized exclusively in the BBM of the proximal tubules (26 -28) .
Npt2a knockout (KO) mice exhibit increased urinary P i excretion, a 50 -70% decrease in renal BBM vesicle Na-P i cotransport, and hypophosphatemia (3, 19) . Npt2a KO mice also overexpress Npt2c, which may support residual renal P i reabsorption function (24) . Laboratory and bone abnormalities are more profound in Npt2a Ϫ/Ϫ Npt2c Ϫ/Ϫ double knockout (DKO) mice than in animals with ablation of only one transporter (Npt2a or Npt2c), indicating that both molecules have similar nonredundant roles in P i homeostasis in rodents and humans.
Dietary P i and parathyroid hormone (PTH) are two major phosphaturic factors that regulate NaPi-IIa and NaPi-IIc in the proximal tubular cells (11, 12) . Tenenhouse and coworkers (24, 30) investigated whether dietary P i and PTH affect renal P i reabsorption in Npt2a KO mice and reported that neither phosphaturic factor affected the levels of BBM Na/P i transport activity in Npt2a KO mice. Thus, in Npt2a KO mice, dietary P i and PTH do not seem to act on Npt2c in the short term. The role of Npt2c in renal P i reabsorption, however, is unknown.
The type II NaPi cotransporter Npt2b is the major transporter that mediates P i absorption in the intestine. Sabbagh et al. (14) recently demonstrated that serum P i and calcium concentrations are maintained in Npt2b-inducible conditional KO mice devoid of measureable Npt2b, despite clear evidence of decreased intestinal P i uptake. Npt2b KO mice exhibit increased levels of Npt2a protein in the renal proximal tubules relative to those in wild-type (WT) mice, indicating that Npt2b KO mice respond appropriately to decrease intestinal P i uptake by increasing P i reabsorption. Thus the three transporters (Npt2 family) may maintain systemic P i homeostasis by assisting each other's functions.
Fibroblast growth factor 23 (FGF23) is a hormone that promotes renal P i excretion by decreasing P i reabsorption in the proximal tubules while concurrently reducing plasma 1,25(OH) 2 D 3 by both decreasing its biosynthesis and increasing its metabolism (1, 13, 22, 23) . FGF23 requires an additional cofactor, klotho, to bind with high affinity and signal efficiently through its cognate FGF receptor (9, 25) . Klotho and FGF receptor 1 (IIIc) form a heterodimeric receptor for FGF23 (9, 25) . We previously reported that administration of FGF23 containing the R179Q mutation (FGF23M) decreases Na/P i transport activity and Npt2a and Npt2c expression levels (8, 18) . Reduced plasma levels of 1,25(OH) 2 D 3 may suppress intestinal Npt2b levels, but the detailed mechanisms of how the three transporters (Npt2 family) are regulated by FGF23 are not known.
In the present study, we used Npt2a KO, Npt2c KO, and DKO mice to investigate the roles of Npt2a, Npt2b, Npt2c, and PiT-2 in FGF23-mediated regulation of renal P i reabsorption.
MATERIALS AND METHODS
Mice. Male C57BL/6 mice were purchased from Charles River Laboratories Japan (Yokohama, Japan). Male and female Npt2a ϩ/Ϫ mice were purchased from Jackson Laboratory (Bar Harbor, ME) (3). Crossing male and female Npt2a ϩ/Ϫ mice yielded Npt2a Ϫ/Ϫ mice. Npt2c-deficient mice were generated by gene targeting (20) . Crossing male and female Npt2c ϩ/Ϫ mice yielded Npt2c Ϫ/Ϫ mice. Crossing Npt2a Ϫ/Ϫ and Npt2c Ϫ/Ϫ mice yielded double-heterozygous animals (Npt2a ϩ/Ϫ Npt2c ϩ/Ϫ ). Both Npt2a Ϫ/Ϫ and Npt2c Ϫ/Ϫ mice have a C57BL/6J genetic background. Successive crosses of these mice yielded Npt2a
Ϫ/Ϫ Npt2c Ϫ/Ϫ (DKO) mice. Mice were genotyped by PCR amplification of genomic DNA. PCR typing of genomic DNA was performed using Ampdirect (Shimazu, Kyoto, Japan). Three PCR primers were used to genotype the Npt2a and Npt2c as described previously (19, 20) . Metabolic cages were used for 24-h urine collection from mice. Mice were maintained under pathogen-free conditions and handled in accordance with the Guidelines for Animal Experimentation of the Tokushima University School of Medicine.
FGF23 mutant DNA and injection of naked DNA. DNA encoding human FGF23M was subcloned into the pCAGGS3 expression plasmid as described previously (15, 16) . The pCAGGS3 expression plasmid vector was kindly provided by Dr. Jun-ichi Miyazaki (Osaka University, Osaka, Japan). The empty plasmid vector was used as a mock control. For DNA injection, TransIT-EE Hydrodynamic Delivery Solution was used as the TransIT in vivo gene delivery system (Takara, Osaka, Japan) (8, 15, 16, 18) . When mice were 7 wk of age or had reached a body weight of ϳ20 g, 2 ml of DNA solution containing 10 g of the expression plasmid (FGF23R179Q or empty plasmid) was administered intravenously. At 6 days after the injection of naked DNA, blood samples were obtained from the abdominal vein, and tissues were rapidly removed under anesthesia.
Plasma and urine parameters. Concentrations of plasma and urinary inorganic calcium and P i were determined using Calcium-E and Phospha-C tests (both from Wako, Osaka, Japan), respectively. Concentrations of urinary creatinine (Cr) were determined using a Creatinine-Wako test (Wako). Concentrations of plasma 1,25(OH) 2D3 were determined by a radio-receptor assay (SRL, Tokyo, Japan). Concentrations of plasma FGF23 protein were determined using a FGF-23 ELISA kit (Kainos Laboratories, Tokyo, Japan).
RNA analysis. Total RNA was extracted from mouse tissues using Isogen (Nippon Gene, Tokyo, Japan). After DNase treatment, cDNA was synthesized using the Moloney murine leukemia virus, reverse transcriptase (Invitrogen, Carlsbad, CA), and oligo(dT)12-18 primer. The PCR reactions were initiated with denaturation at 95°C for 3 min, followed by amplification at 95°C for 30 s, 58°C for 30 s, and 72°C for 30 s for 35 cycles. PCR primer sequences were as follows: FGF23, 5-gctctgggtctgtgccttgt-3= and 5=-gtgatactgaggagagtg-3=; and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 5=-ctgcaccaccactgcttagc-3= and 5=-catccacagtcttctgggtg-3=.
Quantitative PCR. Quantitative PCR was performed using ABI PRISM 7500 (Applied Biosystems, Foster City, CA). The reaction mixture consisted of 10 l of SYBR Premix Ex Taq (Perfect Real Time, Takara) with specific primers. The PCR reactions were initiated with denaturation at 95°C for 10 s, followed by amplification with 50 cycles at 95°C for 10 s, annealing at 60°C for 15 s, and 72°C for 15 s. Data were evaluated with SDS v. 1.2.X with RQ software. PCR primer sequences were as follows: 25-hydroxyvitamin D-1␣-hydroxylase (1␣-OHase), 5=-gagcaaactccaggaagcag-3= and 5=-tgaggaatgatcaggagagg-3=; 25-hydroxyvitamin D-24-hydroxylase (24-OHase), 5=-tgggaagatgatggtgaccc-3= and 5=-tcgatgcagggattgactg-3=; klotho, 5=-caatggctttcctcctttac-3= and 5=-tgcacatcccacagatagac-3=; early growth-responsive 1 (EGR-1), 5=-tatgagcacct- gaccacagtc-3= and 5=-gctgggataactcgtctccacc-3=; and GAPDH, 5=-ctgcaccaccaactgcttagca-3= and 5=-catccacagtcttctgggtg-3=.
Immunoblotting. Protein samples were heated at 95°C for 5 min in sample buffer in the presence of 5% 2-mercaptoethanol and subsequently subjected to 8% SDS-PAGE. The separated proteins were transferred by electrophoresis to a polyvinylidene difluoride transfer membrane (Immobilon-P, Millipore, Billerica, MA). The membrane was treated with diluted rabbit affinity-purified anti-Npt2a (1:5,000), anti-Npt2c (1:500) (17); anti-PiT2 (1:3,000, PiT-2 antibody was kindly provided by Dr. M. Levi, Dept. of Medicine, University of Colorado Denver, School of Medicine), anti-Npt2b (1:1,000; Alpha Diagnostic, San Antonio, TX), or mouse affinity-purified anti-actin (1: 5,000; Chemicon, Temecula, CA) antibodies as an internal control, followed by treatment with horseradish peroxidase-conjugated antirabbit or mouse IgG (Jackson ImmunoResearch Laboratories, West Grove, PA). Signals were detected using Immobilon Western Chemiluminescent HRP Substrate (Millipore).
Immunohistochemical analysis. Immunohistochemical analysis of mouse kidney sections was performed as described previously (17, 18, 20) . For immunostaining, serial sections (5 m thick) were incubated with affinity-purified anti-Npt2a (1:1,000) or Npt2c (1:100) antibodies overnight at 4°C. Sections were then treated with Envision (ϩ) rabbit peroxidase (Dako) for 30 min at room temperature. Immunoreactivity was detected by treatment with ImmPACT DAB Peroxidase Substrate (Vector Laboratories, Burlingame, CA).
Transport assay. BBM vesicles were prepared from mouse kidneys using the Ca 2ϩ precipitation method, as described previously (20, 29) . The levels of alkaline phosphatase in whole homogenates and BBM vesicles were measured to assess membrane purity. The transport rate of phosphate into renal BBM vesicles was determined at 30 s, 60 s, and 60 min (equilibrium value) at 25°C with an inward gradient of 100 mM NaCl 2 or 100 mM KCl and 0.1 mM KH2PO4 (pH 7.5). All measurements were performed in triplicate.
Statistical analysis. Data are expressed as means Ϯ SD. Differences among multiple groups were analyzed by analysis of variance. Differences between two groups were analyzed using Student's t-test. A P value of Ͻ0.05 was considered statistically significant. Fig. 1 . The plasma P i concentration was significantly lower in Npt2a KO mice than in WT and Npt2c KO mice (Fig. 1A) , as described previously (3, 20) . The plasma Ca concentration was significantly higher in Npt2a KO mice than in WT and Npt2c KO mice (Fig. 1B) (3, 20) . The plasma 1,25(OH)2D3 concentration was significantly higher in Npt2a KO and Npt2c KO mice than in WT mice (Fig. 1C) (3, 20) . In addition, the plasma FGF23 concentration was significantly lower in Npt2a and Npt2c KO mice than in WT mice ( Fig. 1D) (3, 20) . Npt2a protein was not detected in renal BBM vesicles from Npt2a KO mice, and Npt2c protein levels were significantly increased in Npt2a KO mice (Fig. 1E) . In contrast, Npt2a protein levels were not different between Npt2c KO mice and WT mice (20, 24) .
RESULTS

Comparison of plasma
Expression of human FGF23 in mice injected with FGF23M. Injection of naked DNA plasmids encoding the human FGF23 gene into animals resulted in the expression of FGF23 protein in the liver (8) . Only FGF23M, but not WT FGF23, was secreted in the blood (8) . In this study, we injected mice with FGF23M and a mock vector. To confirm external human FGF23M expression, we examined human FGF23M mRNA expression in the liver and measured the plasma FGF23 concentration (Fig. 2) . At 6 days after FGF23M injection, human FGF23 mRNA was present in the liver of the FGF23M groups but not in mock controls (Fig. 2I) . In addition, the plasma FGF23 concentration was significantly increased in mice injected with FGF23M compared with mock controls (Fig. 2II) .
Plasma parameters and urinary P i excretion in WT, Npt2a KO, and Npt2c KO mice injected with FGF23M. The plasma P i concentration was significantly decreased in mice injected with FGF23M compared with mock groups (Fig. 3I) . In particular, Npt2a KO mice injected with FGF23M had severe hypophosphatemia compared with WT mice injected with FGF23M (Fig. 3Ib) . Plasma P i levels were decreased by ϳ80% in Npt2a KO mice [to 20.81% (3.36%) of mock control] and by ϳ30% in WT mice [to 69.76% (1.39%) of mock control; Fig. 3I, a and  b] . In addition, the plasma P i concentration was decreased by ϳ43% in Npt2c KO mice [to 57.41% (3.42%) of mock control; Fig. 3Ic ].
After injection of FGF23, plasma P i levels were significantly lower in Npt2c KO mice than WT mice (Fig. 3I, a and c) . The plasma Ca concentrations were not significantly different between FGF23M-treated mice (Fig. 3II) . The plasma 1,25(OH) 2 D 3 concentration was markedly decreased in mice injected with FGF23M compared with the mock controls (Fig. 3III) . The P i /Cr ratio and the fractional excretion index of P i (FEI Pi ) were slightly, but not significantly, increased in both WT mice and Npt2c KO mice injected with FGF23M compared with the mock controls (Fig. 3IV, a and c, and V, a and c) . In contrast, the P i /Cr ratio and FEI Pi were significantly increased in the Npt2a KO mice injected with FGF23M compared with the Npt2a KO mock control group (Fig. 3IVb) .
Effect of injection of FGF23M on levels of renal Na/P i transport activity and Npt2a and Npt2c expression levels in WT, Npt2a KO, and Npt2c KO mice. We then investigated Na ϩ -dependent P i (Na/P i ) transport activity in isolated BBM vesicles from the mutant mice. The renal Na/P i transport activity levels were significantly decreased in all mice injected with FGF23M compared with mock controls (Fig. 4) . In Npt2a KO mice, FGF23M significantly decreased Na/P i transport activity levels [to 57.6% (0.55%) of mock control; Fig. 4B ]. In contrast, Na/P i transport activities levels were slightly, but significantly, decreased in WT mice [to 67.2% (0.52%) that of mock control] and Npt2c KO mice [to 81.9% (0.38%) that of mock control] injected with FGF23M compared with mock controls (Fig. 4, A and C) . 4 . Effect of FGF23M on renal Na/Pi transport activity levels in WT, Npt2a KO, and Npt2c KO mice. Na/Pi transport activity was assessed by measuring Pi uptake into the renal brush-border membrane vesicles. Bush-border membrane vesicles were isolated from WT mice (A), Npt2a KO mice (B), and Npt2c KO mice (C), which were injected with empty vector (mock control) or FGF23M. Values are means Ϯ SD. *P Ͻ 0.05 vs. mock control mice in each mouse group; n ϭ 6 -9.
Npt2a and Npt2c protein expression levels were examined using Western blot analysis and immunohistochemical analysis (Figs. 5 and 6 ). FGF23M significantly decreased Npt2a and Npt2c protein expression in WT mice (Fig. 5Ia) . Npt2a protein expression was decreased to 39.5% (13.0%) and Npt2c protein expression was markedly decreased to 0.04% (0.01%) in WT mice injected with FGF23M compared with mock controls (Fig. 5IIa) . In Npt2a KO mice injected with FGF23M, Npt2c protein expression was decreased to 0.28% (0.31%) that of mock controls (Fig. 5, Ib and IIb) . In Npt2c KO mice injected with FGF23M, Npt2a protein expression was decreased to 45.8% (19.9%) of mock controls (Fig. 5, Ic and IIc) . Percent reduction of Npt2c protein levels was greater than that of Npt2a. Similar data were generated by immunohistochemical analyses (Fig. 6) . Injection of FGF23M significantly reduced the renal 1␣-OHase and 24-OHase mRNA levels in all mouse groups (Fig. 7) .
Effects of FGF23M on renal P i transport in Npt2a/Npt2c DKO mice. We previously generated Npt2a/Npt2c DKO mice (19) . DKO mice have severe hypophosphatemia and rickets. Their phenotypes are similar to those of hereditary hypophosphatemic rickets with hypercalciuria, which is characterized by hypophosphatemia, short stature, rickets and/or osteomalacia, low plasma FGF23 levels, and hypercalciuria (19) . We examined the effect of FGF23M administration in DKO mice (Fig. 8) .
In this experiment, we also confirmed the absence of Npt2a and Npt2c expression in DKO mice (data not shown). Human FGF23 mRNA levels in the liver and plasma FGF23 protein levels were significantly higher in DKO mice injected with FGF23M (Fig. 8, A and B) . FGF23M did not affect the plasma P i concentration, the urinary P i /Cr ratio, or FEI Pi in DKO mice (Fig. 8, C-E) . The plasma 1,25(OH) 2 D 3 concentration, however, was significantly reduced in DKO mice injected with FGF23M (Fig. 8F) . Renal Na ϩ -independent and Na ϩ -dependent phosphate transport activities (% of DKO mock control mice) in DKO and Npt2a KO mice injected with FGF23M or mock controls are shown in Fig. 8, G and H . In DKO mice, FGF23M did not affect renal Na ϩ -dependent or Na ϩ -independent phosphate transport activities.
Renal klotho mRNA expression levels were significantly decreased in DKO mice (Fig. 8I) . We then analyzed the expression of EGR-1 mRNA, which is a marker for FGF23/ klotho signaling (Fig. 8J) (26) . After injection of FGF23M, EGR-1 mRNA levels were markedly increased in WT kidneys. A similar increase was detected in DKO mice. These findings suggest that the FGF23/klotho signal functions normally in DKO mice.
We further examined the effect of FGF23 M on renal PiT-2 expression in WT, Npt2a KO, Npt2c KO, and DKO mice (Fig. 9) . PiT-2 expression levels were significantly higher in Npt2a KO mice than in WT mice (Fig. 9, A and B) as described previously (13) . PiT-2 protein expression, however, was not detected in Npt2c KO and DKO mice (Fig. 9, C and D) . FGF23 markedly decreased PiT-2 expression in WT and Npt2a KO mice (Fig. 9,  A and B) . FGF23 administration induced no differences between DKO and Npt2c KO mice (Fig. 9, C and D) . Finally, we examined the effect of FGF23M administration on intestinal Npt2b expression in WT, Npt2a KO, Npt2c KO, and DKO mice (Fig. 10) . As described previously, FGF23M decreased the expression of Npt2b in WT mice (Fig. 10A) (10) . In contrast, no prominent effect of FGF23M was observed in Npt2a KO, Npt2c KO or DKO mice (Fig. 10, B-D) .
DISCUSSION
In the present study, to clarify the role of Npt2a and Npt2c in P i homeostasis, we injected FGF23M into three types of mutant mice. First, we analyzed the effect of FGF23 on renal P i transport in Npt2a KO mice. Tenenhouse and coworkers (7, 24, 30) demonstrated that PTH and dietary P i , two important phosphaturic factors, did not alter renal Na/P i transport activity levels in Npt2a KO mice. In the present study, FGF23M administration markedly reduced plasma P i levels, renal Na/P i transport activity levels, and Npt2c protein expression in Npt2a KO mice. These findings indicate that the phosphaturic effects of FGF23/klotho pathway activation differ from those of PTH or dietary P i . In addition, Na ϩ -dependent P i transport activity was markedly decreased in FGF23-treated Npt2a KO mice, whereas Na ϩ -independent P i transport activity was unchanged (data not shown). These findings strongly suggest that renal Npt2c supports renal Na ϩ -dependent P i transport activity and maintains plasma P i levels in Npt2a KO mice. PiT-2, a type III Na ϩ -P i cotransporter, is localized in the apical BBM of the proximal tubules, regulated by dietary P i , and downregulated in K-deficient rats and mice (5, 26) . Using PiT-2-specific antibodies, we observed an upregulation of renal PiT-2 protein in Npt2a KO mice. In addition, FGF23 markedly suppressed PiT-2 protein levels in the kidney of Npt2a KO mice. Therefore, FGF23-dependent phosphaturic action in Npt2a KO mice is dependent on renal Npt2c and PiT-2 proteins.
We also analyzed the phosphaturic action of FGF23 in Npt2c KO mice. Npt2c KO mice exhibit hypercalcemia, hypercalciuria, and increased plasma 1,25(OH) 2 D 3 levels (20) . Na ϩ -dependent P i transport activity in renal BBM vesicles was not decreased in Npt2c KO mice compared with WT mice (20) . In Npt2c KO mice, FGF23 significantly decreased renal P i transport activity and Npt2a protein amounts. In contrast, FGF23 did not affect the levels of PiT-2 in the kidney of Npt2c KO mice. Indeed, in the noninjection group, the levels of PiT2 protein were significantly decreased in Npt2c KO mice compared with those in WT and Npt2a KO mice. The reason for the decrease in PiT2 protein levels in Npt2c KO mice remains unknown. The present findings suggest that the phosphaturic action of FGF23 is dependent on renal Npt2a in Npt2c KO mice. In a previous study, Npt2c KO mice did not exhibit hypophosphatemia or hyperphosphaturia (20) . Therefore, Npt2c may be involved in the calcium/vitamin D system and, to some degree, in P i homeostasis in mice. The phosphaturic action of FGF23 appears to be different between Npt2a KO and Npt2c KO mice.
We also analyzed the phosphaturic action of FGF23 in DKO mice. DKO mice originally exhibited severe hypophosphatemia and rickets/osteomalacia (20) . FGF23 did not increase the severity of hypophosphatemia and hyperphosphaturia in DKO mice. Furthermore, FGF23 did not reduce renal P i transport activity in DKO mice. Interestingly, Npt2a KO mice injected with FGF23M had more severe hypophosphatemia than FGF23-treated DKO mice. Renal PiT-2 protein levels were significantly decreased in DKO mice compared with those in WT and Npt2a KO mice. Moreover, FGF23 did not affect the PiT-2 levels in the kidney of DKO mice. Because DKO mice have P i transport, an unknown P i transport system may be induced in the renal proximal tubules in DKO mice and FGF23 might not downregulate those transporters.
In the present study, we investigated the effect of FGF23 on intestinal Npt2b protein levels. Consistent with a previous study, Npt2b protein levels were significantly decreased after injection of FGF23 (10) . These findings suggest that the effect of FGF23 is mediated by reduced plasma 1,25(OH) 2 D 3 levels, because FGF23 does not affect the Npt2b levels in vitamin D receptor null mice (8) . In contrast, no prominent effect of FGF23 on Npt2b protein levels was observed in Npt2a KO, Npt2c KO, and Npt2a/Npt2c DKO mice, although plasma 1,25(OH) 2 D 3 levels were markedly suppressed in all mutant mice. These findings suggest that the regulation of intestinal Npt2b protein levels may be mediated by a factor(s) other than 1,25(OH) 2 D 3 . These factors may also be involved when dietary P i is low, and they may be important regulators linking the intestine and kidney. Indeed, in a recent study, Sabbagh et al. (14) reported that Npt2b is important for P i homeostasis and demonstrated that organ cross talk, involving the intestine, bone, kidney, and the FGF23/1,25(OH) 2 D 3 hormonal axis, has a physiological role in regulating renal phosphate excretion. Further studies are needed to clarify the 1,25(OH) 2 D 3 -independent regulation of Npt2b in the small intestine.
The exact mechanisms of the FGF23-induced downregulation of Npt2a, Npt2c, and PiT-2 are not known. FGF23 requires an additional cofactor, klotho, to bind and signal through its cognate FGF receptors (9, 25) . Farrow et al. (6) demonstrated that the initial FGF23-mediated signaling in the kidney occurs through mitogen-activated protein kinase in the distal convoluted tubule and is colocalized with klotho. This activity is spatially separated from Npt2a and Npt2c in the proximal tubule, which may allow for fine control of FGF23 bioactivity through nephron segmentspecific events (6) . Klotho mRNA levels in the kidney were significantly decreased in DKO mice compared with WT, Npt2a KO, and Npt2c KO mice. Plasma FGF23 levels are also significantly decreased in DKO mice compared with Npt2a KO mice (19) . Together, these findings suggest that hypophosphatemia downregulates FGF23/klotho signaling in the bone-kidney axis and stimulates an increase in plasma Ca levels by increasing vitamin D synthesis. One possible reason that FGF23 does not affect plasma P i levels is that klotho is downregulated in the distal tubules in DKO mice. Administration of FGF23M into DKO mice, clearly altered the levels of 24-OHase, 1␣-OHase, and EGR-1 mRNA, as described previously (2, 8, 21, 25) . FGF23, however, did not induce phosphaturia in DKO mice. Finally, the findings of the present study indicate that the phosphaturic effects of FGF23 on renal reabsorption are Npt2a dependent and Npt2c dependent. FGF23-induced phosphaturic activity in Npt2a KO mice is dependent on renal Npt2c protein.
In contrast, suppression of vitamin D synthesis by FGF23 affects intestinal Npt2b protein levels in WT mice, but not in Npt2a KO, Npt2c KO, or DKO mice. Thus complementary regulation of Npt2 family proteins may be involved in systemic P i homeostasis.
